
Daraxonrasib, a new breakthrough treatment for pancreatic cancer, has been priced at almost $40,000 USD per month in the United States. This video features a critical appraisal of the RASolute 302 trial, followed by a discussion of how the pricing of daraxonrasib will impact patient access. View it on YouTube: youtu.be/OiXInH7MHcQ #CommonSenseOncology #CancerCare #Daraxonrasib













